Exonic

Exonic, based in the US, specializes in AI-driven precision gene therapy, focusing on optimizing genetic interventions through advanced technology to enhance treatment accuracy for genetic disorders. Founded in 2025 and headquartered in San Francisco, US, Exonic focuses on leveraging artificial intelligence for precision gene therapy. The company has engaged in one investment deal, with the most recent taking place on November 17, 2025. Exonic was established by a team of professionals with extensive backgrounds, though further details on the founders are not available.

Exonic is at the forefront of precision gene therapy, leveraging artificial intelligence to enhance the efficacy and specificity of genetic interventions. The company's core offerings include advanced AI-driven platforms designed to optimize gene editing techniques, aiming to address genetic disorders with unparalleled accuracy. These platforms cater to a diverse clientele that includes research institutions, pharmaceutical companies, and biotechnology firms, providing them with tools necessary for developing targeted treatments. The products are utilized across various geographical markets, including North America, Europe, and parts of Asia, where there is significant demand for innovative gene therapy solutions.

Through their sophisticated technology, Exonic aims to solve critical challenges in the treatment of rare and complex genetic diseases, positioning itself as a leader in the field of precision medicine. Exonic's revenue model is primarily based on partnerships with pharmaceutical and biotech companies, facilitating B2B transactions that are essential for the development of gene therapies. The company engages in collaborative agreements where clients subscribe to Exonic's AI platforms for a set duration, allowing them access to proprietary algorithms and data analytics that enhance their gene therapy research. These partnerships are structured to include milestone payments linked to the development phases of client projects, ensuring that Exonic is rewarded as its technologies contribute to successful outcomes.

While specific pricing details for these services are not publicly disclosed, the business model reflects a commitment to providing high-value solutions that align with the evolving needs of the biotech sector. Exonic's innovative approach to gene therapy not only fosters collaboration but also supports advancements in the treatment landscape for genetic disorders. In November 2025, Exonic raised an undisclosed amount of venture funding from new investors Y Combinator and Pioneer Fund. The company will use the funding to accelerate its growth.

Exonic plans to expand its product offerings and explore new market opportunities, particularly in Europe and Asia, by the end of 2026. This strategic push aims to enhance accessibility to their AI-driven gene therapy solutions, meeting the increasing demand for advanced genetic treatments.